Polaryx Therapeutics (PLYX) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($66.3 million vs $62.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | VTVT |
|---|---|---|
| Share price | $1.33 | $15.51 |
| Market cap | $66.30M | $62.22M |
| 1-day change | -11.92% | -5.20% |
| YTD return | — | -61.22% |
| 1-year return | — | -47.53% |
| 5-year return | — | -71.06% |
| EPS (TTM) | $-0.18 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-8.98M | $-26.97M |
| 52-week high | $48.91 | $44.00 |
| 52-week low | $1.30 | $15.47 |
| Distance from 52-week high | -97.28% | -64.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +463.91% | +261.06% |
| Average volume | 36.42K | 33.07K |
| Shares outstanding | 49.85M | 4.01M |
| Employees | 2 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
PLYX vs VTVT FAQ
Which is bigger, Polaryx Therapeutics or vTv Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $66.30M compared with $62.22M for vTv Therapeutics (VTVT).
Are Polaryx Therapeutics and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.